The Food and Drug Administration approved a new indication for Astellas’ Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension). The ...

Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to ...

The US Food and Drug Administration (FDA) has expanded the indication for Mirabegron (Myrbetriq/Myrbetriq Granules) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to ...

The beta-3 adrenergic agonist mirabegron (Myrbetriq) gained an indication for neurogenic detrusor overactivity (NDO), a form of bladder dysfunction, in children 3 and older, the FDA announced Thursday ...

Both formulations are indicated for patients aged 3 years and older; however, the tablet formulation is specifically approved for patients weighing 35kg or more. The Food and Drug Administration (FDA) ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) said Friday that the U.S. Food and Drug Administration approved Myrbetriq (mirabegron extended-release tablets) for the treatment of NDO in pediatric ...

Zydus is introducing mirabegron extended-release tablets, 25 mg, which is the generic of Myrbetriq. Zydus is among the first suppliers to launch the generic version of mirabegron extended-release ...

TOKYO, March 26, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) approved ...

A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA). Abecma cleared as first cell-based gene therapy for multiple myeloma in adults Bristol Myers ...

Most Medicare drug plans cover the cost of mirabegron (Myrbetriq). But you’ll likely still have out-of-pocket costs. Many of the discount coupons available cannot be used with Medicare. The price may ...